Biotech company developing a novel therapeutic that targets endothelin-1, for chronic kidney disease, diabetes complications, neurological diseases and others
Honoured to be named Pre-Clinical Drug Development Company of the Year by Global Health & Pharma awards
This encouragement fuels our determination as we develop our novel therapeutic targeting multiple disease areas with few existing treatment options
https://t.co/O1oWfpih6a
We are very excited to be presenting our work at the 18th International Conference on Endothelin being held in Rome this week. We have been enjoying the presentations from eminent scientists in the exciting field of endothelin research and looking forward to the remaining talks.
Elevated endothelin-1 has been implicated in a number of diseases including preeclampsia where is induces hypertension, oxidative stress, ER stress, microvascular dysfunction, fibrosis and tissue damage to different organs like the heart and kidneys. Our recent publication in
Our latest publication on the potential therapeutic use of ET-traps in complications of the heart and kidney can be found in the journal of biomedical research and environmental sciences at https://t.co/6IuxpvFVR9
We are honoured to be selected by cpi for their EDRF SPRINT program and look forward to their valuable help and insights in our innovation's commercialization journey.
...ET-traps use in various diseases will not block the functions of the endothelin system completely and thus will avoid side effects.
Published study available at https://t.co/WxJ6svwl2r
We are excited with the findings from our latest study, confirming ET-traps are highly specific to endothelin-1 (ET-1) over its homologues ET-2 and ET-3, further ensuring...
@Fangorn17@dronico Thank you for the shoutout @Fangorn17 and for believing in ET-traps. Wholeheartedly agree, ET-1 is an important target for several diseases. And we are working hard to make ET-traps therapeutic available to combat these.
How do the new KDIGO 2021 Clinical Practice Guidelines for the Management of Blood Pressure in Chronic Kidney Disease affect BP management in patients with CKD? This Kidney Case Conference: How I Treat article provides the details of a real patient case https://t.co/W0i6Jbe5m2
We are excited and honored to be featured by the weekly newspaper of the year as the main story in their business issue. Thank you for your support @CambridgeIndy . We are looking forward to tackling #CKD (and more)
Recent research has shown that increased levels of ET-1 leads to development of autoimmune conditions like MS as well as virus induced demyelinating diseases.ET-traps can be a game changer in treating these conditions! #Endothelin#MS#autoimmunedisease
https://t.co/LN7taHuvfk